Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expiration dates for Trulicity, Mounjaro, and other blockbuster medicines mean every Eli Lilly disclosure can shift expectations for future cash flow. If you have ever searched for Eli Lilly SEC filings explained simply, you know how dense a pharmaceutical 10-K can be. Stock Titan’s AI reads each document the instant it posts to EDGAR and serves a concise summary that highlights clinical-trial outcomes, FDA correspondence, and global pricing risks—turning hundreds of pages into a five-minute briefing.
Need details from the latest Eli Lilly quarterly earnings report 10-Q filing or a quick take on cash used for R&D? Our platform flags segment revenue, pipeline spend, and patent-life tables while linking directly to the full text. The annual report is here as the Eli Lilly annual report 10-K simplified; Form 8-K alerts keep you current with trial readouts and collaborations—see Eli Lilly 8-K material events explained. When proxy season arrives, the Eli Lilly proxy statement executive compensation section breaks down option awards, pay-for-performance metrics, and governance votes, all with clear AI commentary.
Monitoring insider sentiment? Track Eli Lilly insider trading Form 4 transactions and receive Eli Lilly Form 4 insider transactions real-time notifications. Our dashboards group every Eli Lilly executive stock transactions Form 4 with trend charts so you can spot buying or selling patterns before the market reacts. Use the built-in tools for Eli Lilly earnings report filing analysis or simply browse by form if you prefer traditional reading. Whether you’re comparing quarter-over-quarter margins or understanding Eli Lilly SEC documents with AI, this page delivers every filing, every update, in a workflow that saves hours and sharpens your investment decisions.
Lilly Endowment Inc. has filed a Form 144 indicating a planned sale of 310,000 shares of Eli Lilly and Company common stock through J.P. Morgan Securities LLC, with an aggregate market value of
The securities to be sold trace back to common stock originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, in a transaction involving 38,400,000 shares. The notice also details a series of recent block sales of Eli Lilly common stock by Lilly Endowment Inc., including 351,015 shares sold on
By signing, the seller represents that it is not aware of undisclosed material adverse information about Eli Lilly’s current or prospective operations.
Eli Lilly and Company director Kimberly H. Johnson reported buying 215.327 shares of Eli Lilly common stock on 11/17/2025. The Form 4 shows the shares were acquired at a price of
Eli Lilly and Company director Gabrielle Sulzberger reported acquiring additional Eli Lilly (LLY) equity on Form 4. On 11/17/2025, she acquired 4.853 shares of common stock that, at her election, were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after she leaves the board. On the same date, she also acquired 215.327 shares of common stock. Following these transactions, she reported beneficial ownership of 2,948.32 shares of common stock in direct ownership form.
Eli Lilly and Company director reports stock purchase. A reporting person serving as a director of Eli Lilly & Co (LLY) acquired 233.271 shares of common stock on 11/17/2025 at a price of $1,021.7 per share, according to a Form 4 filing. Following this transaction, the director beneficially owns 304.271 shares of Eli Lilly common stock in direct ownership.
Eli Lilly and Company director Juan R. Luciano reported acquiring a total of 229.845 shares of Lilly common stock on 11/17/2025. One transaction covered 14.518 shares that he elected to receive as stock units under the Lilly Directors' Deferral Plan instead of cash compensation, to be settled in shares after his separation from service. A second acquisition of 215.327 shares was also reported at a price of $1,021.7 per share. Following these transactions, Luciano directly beneficially owns 16,704.141 shares of Eli Lilly common stock.
Eli Lilly & Co director William G. Kaelin, Jr. reported an acquisition of company stock on a Form 4. On 11/17/2025, he acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. After this transaction, he beneficially owned a total of 21,836.814 Eli Lilly shares, held in direct ownership.
Eli Lilly & Co (LLY) director Jamere Jackson reported acquiring common stock of the company. On 11/17/2025, the reporting person acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, coded as an acquisition transaction. Following this transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock held directly. The filing was made as a Form 4 by a single reporting person in the capacity of a company director.
Eli Lilly and Company director Mary Lynne Hedley reported acquiring additional common stock of LLY. On 11/17/2025, she acquired 9.706 shares of common stock and a separate 215.327-share award, both shown as acquisitions. The filing shows she beneficially owns 2,240.861 shares directly after these transactions, plus 98 shares held indirectly by a trust. According to the disclosure, the shares in one row were deferred in lieu of cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in common stock after she separates from service.
Eli Lilly & Co. director reports additional stock units from fee deferral
A director of Eli Lilly & Co. (LLY) reported acquiring small amounts of common stock on 11/17/2025, shown as 9.706 and 215.327 shares, through transactions coded as acquisitions. According to the explanation, these amounts represent fees that the director elected to defer in the form of stock units under the Lilly Directors' Deferral Plan instead of taking cash compensation. The filing states these deferred stock units will be settled in shares of common stock after the director separates from service. Following these transactions, the director’s beneficial ownership is listed as 74,988.689 shares held directly.
Eli Lilly & Co (LLY)215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. Following this transaction, she directly beneficially owns 23,502.628 shares of Eli Lilly common stock.
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
What is the market cap of Lilly Eli & Co (LLY)?
